Xspray Pharma AB (publ)

SSE:XSPRAY.ST

44 (SEK) • At close February 20, 2024
Bedrijfsnaam Xspray Pharma AB (publ)
Symbool XSPRAY.ST
Munteenheid SEK
Prijs 44
Beurswaarde 1,375,154,000
Dividendpercentage 0%
52-weken bereik 28.1 - 83.736
Industrie Biotechnology
Sector Healthcare
CEO Dr. Per Andersson Ph.D.
Website https://www.xspraypharma.com

An error occurred while fetching data.

Over Xspray Pharma AB (publ)

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for

Vergelijkbare Aandelen

Senzime AB (publ) logo

Senzime AB (publ)

SEZI.ST

7.25 SEK

ADDvise Group AB (publ) logo

ADDvise Group AB (publ)

ADDV-A.ST

11.6 SEK

Diamyd Medical AB (publ) logo

Diamyd Medical AB (publ)

DMYD-B.ST

13.3 SEK

Cantargia AB (publ) logo

Cantargia AB (publ)

CANTA.ST

3.32 SEK

C-Rad AB (publ) logo

C-Rad AB (publ)

CRAD-B.ST

46.55 SEK

Biovica International AB (publ) logo

Biovica International AB (publ)

BIOVIC-B.ST

2.34 SEK

Paxman AB (publ) logo

Paxman AB (publ)

PAX.ST

38.6 SEK

Isofol Medical AB (publ) logo

Isofol Medical AB (publ)

ISOFOL.ST

0.616 SEK

Infant Bacterial Therapeutics AB (publ) logo

Infant Bacterial Therapeutics AB (publ)

IBT-B.ST

93.4 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)